Actively Recruiting
Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications (VYP)
Led by University Hospital, Brest · Updated on 2024-12-04
200
Participants Needed
1
Research Sites
782 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The creation of a national database will provide access to solid data on the diagnosis of myeloproliferative neoplasia for patients under 30, giving a true picture of their care. It will also make it possible to identify the biological samples (histological and molecular) available in routine laboratories, enabling teams of researchers and anatomopathologists to (re)perform certain analyses to re-evaluate diagnoses and search for hitherto unknown molecular prognostic factors.
CONDITIONS
Official Title
Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications (VYP)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with non-chronic myelogenous leukemia myeloproliferative neoplasm (PV, TE, MFP, PreMF) before age 30 according to 2016 WHO criteria
- Signed consent form for participation in the FIMBANK project
- Agreed to participate in the VYP study
- Patient of legal age at inclusion
- Affiliated with a social security scheme
You will not qualify if you...
- Refusal to participate by patients of full age
- Patient under legal protection such as guardianship or curatorship
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU de Brest
Brest, France, 29609
Actively Recruiting
Research Team
J
Jean-Christophe IANOTTO
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here